Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2 Vaccines: Where Are We Now?
J Allergy Clin Immunol Pract. 2021 10; 9(10):3535-3543.JA

Abstract

The best and safest way to control the coronavirus disease 2019 (COVID-19) pandemic is by using vaccination to generate widespread immunity. The urgent need to develop safe and effective COVID-19 vaccines was met with unprecedented speed and action from the global community. There are now 289 vaccines in the development pipeline. More remarkably, there are 20 publicly available vaccines, and more than 3.3 billion doses of COVID-19 vaccines have been administered across 180 countries. This is just the beginning of our fight against the pandemic. Even at the current vaccination rate, it could take years to vaccinate the world's population; many high-income countries are focusing on their needs, whereas the poorer nations are waiting for vaccines. There is still much that we do not understand about immunity to this new disease, and we will have to contend with the emerging variants. In this commentary, we describe the current status of COVID-19 vaccine development and provide insights into how the development and approvals happened so quickly. We discuss the clinical trial data that led to rapid emergency use authorization and the many challenges of global rollout. We also comment on some of the key unanswered questions and future directions for COVID-19 vaccine development and deployment.

Authors+Show Affiliations

Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, Tas, Australia; School of Medicine, University of Tasmania, Launceston, Tas, Australia; School of Health and Biomedical Science, RMIT University, Bundoora, Vic, Australia; Department of Immunology and Pathology, Monash University, Melbourne, Vic, Australia. Electronic address: katie.flanagan@ths.tas.gov.au.Biosecurity Research Program, Kirby Institute, UNSW Medicine, University of New South Wales, Sydney, NSW, Australia.Women's and Children's Health, University of Otago, Dunedin, New Zealand.Division of Asthma, Allergy and Immunology, University of Virginia, Charlottesville, Va.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

34400116

Citation

Flanagan, Katie L., et al. "SARS-CoV-2 Vaccines: Where Are We Now?" The Journal of Allergy and Clinical Immunology. in Practice, vol. 9, no. 10, 2021, pp. 3535-3543.
Flanagan KL, MacIntyre CR, McIntyre PB, et al. SARS-CoV-2 Vaccines: Where Are We Now? J Allergy Clin Immunol Pract. 2021;9(10):3535-3543.
Flanagan, K. L., MacIntyre, C. R., McIntyre, P. B., & Nelson, M. R. (2021). SARS-CoV-2 Vaccines: Where Are We Now? The Journal of Allergy and Clinical Immunology. in Practice, 9(10), 3535-3543. https://doi.org/10.1016/j.jaip.2021.07.016
Flanagan KL, et al. SARS-CoV-2 Vaccines: Where Are We Now. J Allergy Clin Immunol Pract. 2021;9(10):3535-3543. PubMed PMID: 34400116.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2 Vaccines: Where Are We Now? AU - Flanagan,Katie L, AU - MacIntyre,C Raina, AU - McIntyre,Peter B, AU - Nelson,Michael R, Y1 - 2021/08/13/ PY - 2021/05/17/received PY - 2021/07/08/revised PY - 2021/07/13/accepted PY - 2021/8/18/pubmed PY - 2021/10/14/medline PY - 2021/8/17/entrez KW - COVID-19 vaccines KW - DNA KW - Efficacy KW - Platforms KW - RNA KW - Regulatory pathway KW - Vaccination program KW - Viral vector SP - 3535 EP - 3543 JF - The journal of allergy and clinical immunology. In practice JO - J Allergy Clin Immunol Pract VL - 9 IS - 10 N2 - The best and safest way to control the coronavirus disease 2019 (COVID-19) pandemic is by using vaccination to generate widespread immunity. The urgent need to develop safe and effective COVID-19 vaccines was met with unprecedented speed and action from the global community. There are now 289 vaccines in the development pipeline. More remarkably, there are 20 publicly available vaccines, and more than 3.3 billion doses of COVID-19 vaccines have been administered across 180 countries. This is just the beginning of our fight against the pandemic. Even at the current vaccination rate, it could take years to vaccinate the world's population; many high-income countries are focusing on their needs, whereas the poorer nations are waiting for vaccines. There is still much that we do not understand about immunity to this new disease, and we will have to contend with the emerging variants. In this commentary, we describe the current status of COVID-19 vaccine development and provide insights into how the development and approvals happened so quickly. We discuss the clinical trial data that led to rapid emergency use authorization and the many challenges of global rollout. We also comment on some of the key unanswered questions and future directions for COVID-19 vaccine development and deployment. SN - 2213-2201 UR - https://www.unboundmedicine.com/medline/citation/34400116/SARS_CoV_2_Vaccines:_Where_Are_We_Now L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-2198(21)00804-7 DB - PRIME DP - Unbound Medicine ER -